Oncotarget

Research Papers:

A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds

Marsha L. Crochiere _, Erkan Baloglu, Boris Klebanov, Scott Donovan, Diego del Alamo, Margaret Lee, Michael Kauffman, Sharon Shacham and Yosef Landesman

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:1863-1877. https://doi.org/10.18632/oncotarget.6495

Metrics: PDF 1061 views  |   HTML 1628 views  |   ?  


Abstract

Marsha L. Crochiere1, Erkan Baloglu1, Boris Klebanov1, Scott Donovan1, Diego del Alamo1, Margaret Lee1, Michael Kauffman1, Sharon Shacham1, Yosef Landesman1

1All authors are current or former employees of Karyopharm Therapeutics Inc., Newton, MA, 02459 U.S.A

Correspondence to:

Marsha L. Crochiere, e-mail: marsha@karyopharm.com

Keywords: selinexor, export, occupancy, cancer, resistance

Received: August 06, 2015     Accepted: November 18, 2015     Published: December 07, 2015

ABSTRACT

Selective Inhibitor of Nuclear Export (SINE) compounds are a family of small-molecules that inhibit nuclear export through covalent binding to cysteine 528 (Cys528) in the cargo-binding pocket of Exportin 1 (XPO1/CRM1) and promote cancer cell death. Selinexor is the lead SINE compound currently in phase I and II clinical trials for advanced solid and hematological malignancies. In an effort to understand selinexor-XPO1 interaction and to establish whether cancer cell response is a function of drug-target engagement, we developed a quantitative XPO1 occupancy assay. Biotinylated leptomycin B (b-LMB) was utilized as a tool compound to measure SINE-free XPO1. Binding to XPO1 was quantitated from SINE compound treated adherent and suspension cells in vitro, dosed ex vivo human peripheral blood mononuclear cells (PBMCs), and PBMCs from mice dosed orally with drug in vivo. Evaluation of a panel of selinexor sensitive and resistant cell lines revealed that resistance was not attributed to XPO1 occupancy by selinexor. Administration of a single dose of selinexor bound XPO1 for minimally 72 hours both in vitro and in vivo. While XPO1 inhibition directly correlates with selinexor pharmacokinetics, the biological outcome of this inhibition depends on modulation of pathways downstream of XPO1, which ultimately determines cancer cell responsiveness.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 6495